Business Context and Reporting Period
Purple Biotech Ltd., a foreign private issuer that files annual reports on Form 20-F, furnished this Form 6-K for October 2026. The report announces a chief executive transition effective October 5, 2026.
Leadership Change
- Director and former CEO Isaac Israel was appointed Interim CEO pending appointment of a permanent CEO. Israel has served on the Board since 2012 and previously served as CEO from 2012 to 2022, as well as Acting CEO from March to August 2023.
- Gil Efron ceased serving as CEO and transitioned to Executive Director, Head of Corporate Development. He remains on the Board.
Financial Metrics and Outlook
This filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial results. It provides no financial guidance or outlook.
Other Disclosures
The report is incorporated by reference into specified existing Form S-8 and Form F-3 registration statements. No additional contingencies or unusual financial items are disclosed in the provided text.
Important Facts to Verify
- Appointment and responsibilities of the permanent CEO when named.
- Any subsequent disclosures about the transition, including changes to management arrangements or financial outlook.